Overview

Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)

Status:
Completed

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

The Temprano trial is based on the following assumptions: - ART initiation at CD4 counts <800/mm3 could significantly reduce the probability of severe HIV-related morbidity or death in the medium term. - Tuberculosis and tuberculosis-related deaths are likely to represent a considerable proportion of morbidity and mortality among HIV-infected patients with high CD4 counts in sub-Saharan Africa. Therefore, 6-month Isoniazide Prophylaxis for Tuberculosis (IPT) and early ART could enhance each others efficacy.

Phase:

Phase 3

Details

Lead Sponsor:

French National Agency for Research on AIDS and Viral Hepatitis

Collaborators:

Gilead Sciences
Merck Sharp & Dohme Corp.

Treatments:

Anti-Retroviral Agents
Isoniazid